Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 13/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 11/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4291251 | 0.79 | REN (0.40) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| Hydrochloric Acid SCHEMBL4751926 | 0.79 | REN (0.40) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL4286065 | 0.77 | USP7 (0.36) | — | |
| SCHEMBL4293871 | 0.76 | HPGD (0.51) | SMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL4283648 | 0.75 | LMNA (0.43) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4290177 | 0.74 | LMNA (0.45) | SMN1; SMN2KDM4ELMNA | |
| SCHEMBL4291290 | 0.73 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1LMNAUSP2 | |
| SCHEMBL4552154 | 0.73 | STAT3 (0.51) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4281619 | 0.73 | STAT3 (0.51) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL4285897 | 0.72 | KMO (0.51) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SMN1; SMN2 4811/4885KDM4E 760/4885ALDH1A1 388/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SMN1; SMN2 4811/4885KDM4E 760/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.